The failing diabetic heart: Focus on diastolic left ventricular dysfunction

Current Diabetes Reports

Volumn 9, Issue 1, 2009, Pages 79-86

  Heerebeek, Loek ^b   Somsen, Aernout ^b   Paulus, Walter J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM; COLLAGEN TYPE 1; CONNECTIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPLERENONE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; NESIRITIDE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SILDENAFIL; SODIUM CALCIUM EXCHANGE PROTEIN; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CALCIUM HOMEOSTASIS; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; DIASTOLIC DYSFUNCTION; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR;

CYCLIC GMP; DIABETIC ANGIOPATHIES; DIASTOLE; EXTRACELLULAR MATRIX; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART; HEART FAILURE, DIASTOLIC; HUMANS; INCIDENCE; INFLAMMATION; MYOCARDIUM; NITRIC OXIDE; OXIDATIVE STRESS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 59749101436     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0014-9     Document Type: Review

References (49)

1. Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27: 1047-1053.
2. Bertoni AG, Hundley WG, Massing MW, et al.: Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004, 27: 699-703.
3. Sobel BE: Optimizing cardiovascular outcome in diabetes mellitus. Am J Med 2007, 120: S3-S11.
4. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003, 289: 194-202.
5. Klapholz M, Maurer M, Lowe AM, et al.: Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: Results of the New York Heart Failure Registry. J Am Coll Cardiol 2004, 43: 1432-1438.
6. Owen TE, Redfield MM: Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005, 47: 320-332.
7. van Heerebeek L, Hamdani N, Handoko ML, et al.: Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008, 117: 43-51.
8. de las Fuentes L, Brown AL, Mathews SJ, et al.: Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J 2007, 28: 553-559.
9. Boudina S, Abel ED: Diabetic cardiomyopathy revisited. Circulation 2007, 115: 3213-3223.
10. Zarich SW, Arbuckle BE, Cohen LR, et al.: Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol 1988, 12: 114-120.
11. Boyer JK, Thanigaraj S, Schechtman KB, et al.: Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004, 93: 870-875.
12. Asbun J, Villarreal FJ: The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006, 47: 693-700.
13. Hartog JW, Voors AA, Bakker SJ, et al.: Advanced glycation end-products (AGEs) and heart failure: Pathophysiology and clinical implications. Eur J Heart Fail 2007, 9: 1146-1155.
14. Goldin A, Beckman JA, Schmidt AM, et al.: Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006, 114: 597-605.
15. Witteles RM, Fowler MB: Insulin-resistant cardiomyopathy clinical evidence, mechanisms and treatment options. J Am Coll Cardiol 2008, 51: 93-102.
16. Diamant M, Lamb HJ, Groeneveld Y, et al.: Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003, 42: 328-335.
17. Hartge MM, Unger T, Kintscher U: The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res 2007, 4: 84-88.
18. Fischer D, Rossa S, Landmesser U, et al.: Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation or death. Eur Heart J 2005, 26: 65-69.
19. Jay D, Hitomi H, Griendling KK: Oxidative stress and diabetic vascular complications. Free Radic Biol Med 2006, 40: 183-192.
20. Hare JM, Stamler JS: NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005, 115: 509-517.
21. Pacher P, Szabo C: Role of peroxynitrite in the pathogenesis of cardiovascular complications in diabetes. Curr Opin Pharmacol 2006, 6: 136-141.
22. Föstermann U, Münzel T: Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation 2006, 113: 1708-1714.
23. Paulus WJ, Bronzwaer JG: NitCic oxide's role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol 2004, 287: H8-H13.
24. Kass DA, Takimoto E, Nagayama T, et al.: Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res 2007, 75: 303-314.
25. McKinsey TA, Kass DA: Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov 2007, 6: 617-635.
26. Nagendran J, Archer SL, Soliman D, et al.: Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007, 116: 238-248.
27. Liu S, Ma X, Gong M, et al.: Glucose down-regulation of cGMP-dependent protein kinase I expression in vascular smooth muscle cells involves NAD(P) oxidase-derived reactive oxygen species. Free Radic Biol Med 2007, 42: 852-863.
28. Oelze M, Mollnau H, Hoffmann N, et al.: Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 2000, 87: 999-1005.
29. Su J, Zhang Q, Moalem J, et al.: Functional effects of C-type natriuretic peptide and nitric oxide are attenuated in hypertrophic myocytes from pressure-overloaded mouse hearts. Am J Physiol Heart Circ Physiol 2005, 288: H1367-H1373.
30. Borbely A, van der Velden J, Papp Z, et al.: Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005, 111: 774-781.
31. van Heerebeek L, Borbely A, Niessen HW, et al.: Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113: 1966-1973.
32. Linke WA: Sense and Ttretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc Res 2008, 77: 637-648.
33. Hamdani N, Borbely A, Boontje N, et al.: Protein kinase G corrects high cardiomyocyte resting tension in diastolic heart failure. Circulation 2007, 116: II-708.
34. Krüger M, dos Remedios C, Linke WA: Titin phosphorylation by protein kinases A and G in normal and failing human hearts decreases myocardial passive stiffness. Circulation 2007, 116: II-301.
35. Rubler S, Dlugash J, Yuceoglu YZ, et al.: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972, 30: 595-602.
36. Bertoni AG, Tsai A, Kasper EK, et al.: Diabetes and idiopathic cardiomyopathy: A nationwide case-control study. Diabetes Care 2003, 26: 2791-2795.
37. McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91: 30H-37H.
38. Nickenig G: Should angiotensin II receptor blockers and statins be combined? Circulation 2004, 110: 1013-1020.
39. Gonzalez A, Lopez B, Querejeta R, et al.: Cardiac reninangiotensin aldosterone system: Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol 2002, 34: 1585-1593.
40. Kawasaki D, Kosugi K, Waki H: Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients-reversal by chronic angiotensin II type 1A receptor blockade. Circ J 2007, 71: 524-529.
41. KalidindA SR, Tang WH, Francis GS: Drug insight: aldosterone-receptor antagonists in heart failure-the journey continues. Nat Clin Pract Cardiovasc Med 2007, 4: 368-378.
42. LipinskiSMJ, Abbate A, Fuster V, et al.: Drug insight: statins for nonischemic heart failure-evidence and potential mechanisms. Nat Clin Pract Cardiovasc Med 2007, 4: 196-205.
43. Libby P, Plutzky J: InflammatRon in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 2007, 99: 27B-40B.
44. McGuire DK, Inzucchi SE: New drugs for the treatment of diabetes mellitus: Part 1: Thiazolidinediones and their evolving cardiovascular implications. Circulation 2008, 117: 440-449.
45. Taylor AL, Ziesche S, Yancy CW, et al.: Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: Consistency across subgroups in the African-American Heart Failure Trial. Circulation 2007, 115: 1747-1753.
46. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362: 316-322.
47. Yancy CW, Krum H, Massie BM, et al.: Safety and efficacy of outpatient nesiritide in patients with advanced heart failure; results of the second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail 2008, 1: 9-16.
48. Kass DA, Champion HCE Beavo JA: Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007, 101: 1084-1095.
49. Palumbo PJ: Metabolic risk factors, endothelial dysfunction and erectile dysfunction in men with diabetes. Am J Med Sci 2007, 334: 466-480.